Entera Bio Announces Presentations Of New Data Supporting Its Oral Peptide Pipeline At The Annual Endochrine Society Meeting On June 13-16
Benzinga·05/28/2026 12:54:47
Listen to the news
- Abstract Title: Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 Study
Session Title: Late-Breaking Oral Abstract/Rapid-Fire II
Session Date/Time: Sunday, June 14, 2026, 3:30 – 4:15 PM CT - Abstract Title: Pre-Clinical Results for EB612: First-in-Class Oral Long-Acting PTH(1-34) Analog as Hormone Replacement Tablet for Patients with Hypoparathyroidism
Session Date/Time: Monday, June 15, 2026, 12:00 – 1:30 PM CT - Abstract Title: EB618, First-in-Class Oral Tablet of Dual GLP-1/Glucagon Receptor Agonist for Patients with Obesity and Metabolic Disorders: Results from PK-PD Study in Non-Human Primates
Session Date/Time: Saturday, June 13, 2026, 12:15 – 1:45 PM CT
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.